Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-cash Items (2016 - 2019)

Akebia Therapeutics (AKBA) has disclosed Non-cash Items for 3 consecutive years, with $3.2 million as the latest value for Q4 2019.

  • On a quarterly basis, Non-cash Items rose 34.95% to $3.2 million in Q4 2019 year-over-year; TTM through Dec 2019 was $3.2 million, a 34.95% increase, with the full-year FY2019 number at $3.2 million, up 34.95% from a year prior.
  • Non-cash Items was $3.2 million for Q4 2019 at Akebia Therapeutics, up from $2.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $21.9 million in Q4 2017 to a low of $2.4 million in Q4 2018.
  • A 3-year average of $9.2 million and a median of $3.2 million in 2019 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 89.28% in 2018, then soared 34.95% in 2019.
  • Akebia Therapeutics' Non-cash Items stood at $21.9 million in 2017, then plummeted by 89.28% to $2.4 million in 2018, then soared by 34.95% to $3.2 million in 2019.
  • Per Business Quant, the three most recent readings for AKBA's Non-cash Items are $3.2 million (Q4 2019), $2.4 million (Q4 2018), and $21.9 million (Q4 2017).